PVI-SHAM-AF 试验:导管消融与假手术对症状性房颤患者 6 个月生活质量的影响
PVI-SHAM-AF 为在德国和波兰 9 个中心进行的双盲、多中心、随机假手术对照试验,纳入症状性阵发性或持续性房颤患者,按 2:1 随机分为导管消融组与假手术组。主要终点是 AFEQT 生活质量评分从基线到 6 个月变化的组间差异。结果导管消融组未显示出优于假手术组的房颤相关生活质量改善。
要点
- 导管消融未在 6 个月 AFEQT 生活质量评分改善上优于假手术。
- 两组不良事件均较低,各有 1 例死亡且均与操作无关。
- 假手术对照在房颤消融研究中可行,需关注预期效应。
核心结论
- 导管消融在改善房颤相关生活质量方面未在 6 个月时显示优于假手术。
研究设计与样本
- 双盲、多中心、随机假手术对照试验,在德国和波兰 9 个研究地点开展。
- 纳入年龄 18 岁及以上的症状性阵发性或持续性房颤患者,按 2:1 随机分配至导管消融组或假手术组。
- 使用自动在线随机系统,采用可变区组大小并按研究地点分层。
- 主要分析在意向治疗人群中进行,缺失数据采用多重插补处理。
主要发现
- 173 例患者随机至导管消融组,89 例至假手术组,中位随访 184 天。
- 1 例缺血性卒中发生在假手术组,另有 6 例与操作相关或可能相关严重不良事件在消融组、4 例在假手术组。
关键数值与推荐
- 主要终点为 AFEQT 总分从基线到 6 个月变化的组间差异。
临床怎么用
- 对以改善生活质量为主要目标的症状性房颤患者,导管消融的额外获益在 6 个月时可能有限。
- 临床决策中需向患者说明安慰剂效应可能解释部分症状缓解。
局限性
- 12 个月随访仍在进行中,长期结果尚未报告。
- 未提供两组基线抗心律失常药物使用或消融成功率等具体信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines recommend catheter ablation for symptom relief in patients with atrial fibrillation. The aim of this trial was to ascertain whether catheter ablation improves atrial fibrillation-related quality of life more than a sham procedure. METHODS: PVI-SHAM-AF was a double-blind, multicentre, randomised trial conducted at nine study sites in Germany and Poland. Patients aged 18 years or older with symptomatic paroxysmal or persistent atrial fibrillation were randomly assigned in a 2:1 ratio to catheter ablation or a sham procedure using an automated online randomisation system with variable block sizes, stratified by trial site. The primary endpoint was the between-group difference in change from baseline to 6 months in the Atrial Fibrillation Effect on the Quality-of-life Questionnaire (AFEQT) summary score. The prespecified primary analysis was done in the intention-to-treat population and included all randomly assigned patients, with missing data handled by multiple imputation. This trial is registered with ClinicalTrials.gov (NCT05119231) and 12-month follow-up is ongoing. FINDINGS: Between Nov 12, 2021, and Nov 3, 2025, 1199 patients were invited to participate in the study and 262 patients consented and were randomly assigned: 173 patients to catheter ablation and 89 to sham. The median age was 67 years (IQR 62-73); 134 (51%) were female and 128 (49%) were male. Median follow-up was 184 days (IQR 181-191). At 6 months, the mean AFEQT summary score had increased from 61·3 (SD 20·1) to 81·1 (16·6) in the catheter ablation group and from 59·2 (19·0) to 74·9 (19·5) in the sham control group. The Hodges-Lehmann estimate of the between-group difference in change was 2·6 (95% CI -2·7 to 8·0; p=0·36). One death occurred in each group; neither was considered related to the study procedure. Serious adverse events adjudicated as related or possibly related to the study procedure occurred in ten unique patients: six patients in the catheter ablation group and four patients in the sham control group. One of these was an ischaemic stroke occurred in the sham control group. INTERPRETATION: Catheter ablation did not demonstrate superiority over a sham procedure for improving atrial fibrillation-related quality of life at 6 months. FUNDING: Helios Gesundheit (Förderung Leipziger Herzmedizin).
引用
- Wachter, Haag, Uhe, et al. Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF): a randomised, double-blind, sham-controlled, multicentre trial. Lancet. 2026. PMID: 42669307. doi:10.1016/S0140-6736(26)01558-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。